Ningxia Qiyuan Chinese Medicine Co., Ltd

Ningxia Qiyuan Chinese Medicine Co., Ltd. is a wholly-owned subsidiary of Qiyuan Industrial Investment and a recognized high-tech enterprise, established in 2001. Integrating R&D, production, and sales, the company has received various regional designations, including "Enterprise Technology Center," "Ningxia Traditional Chinese Medicine Innovation Center," and "Specialized, Refined, and Innovative Demonstration Enterprise." The company possesses the manufacturing capabilities to produce both Western and Traditional Chinese medicinal preparations—encompassing five major dosage forms: tablets, granules, capsules, pills, and suppositories—as well as health foods and herbal extracts. Its core product portfolio includes the Jinlian Qingre series, Goji Berry series, Hawthorn Extract Lipid-Lowering series, and Vitamin C series. Upholding the corporate mission of "Building a Global Reputation, Promoting Health Across China" and the core values ​​of "Caring for Employees, Championing Innovation," the company has emerged as a key enterprise within Ningxia's pharmaceutical industry.